Human Immunology News 6.38 September 25, 2018 | |
| |
TOP STORYT Cells in Patients with Narcolepsy Target Self-Antigens of Hypocretin Neurons Researchers used sensitive cellular screens and detected hypocretin-specific CD4+ T cells in all 19 patients that were tested; T cells specific for tribbles homologue 2—another self-antigen of hypocretin neurons—were found in 8 out of 13 patients. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors used proteomic approaches and patient-derived B-cell lymphoma cell lines to investigate mechanisms that regulate PD-L1 expression. They found that PD-L1 expression, particularly in non-germinal center B cell-derived diffuse large B-cell lymphoma, is controlled and regulated by several interactive signaling pathways, including the B-cell receptor and JAK2/STAT3 signaling pathways. [Blood] Abstract Researchers showed that Sox4 was a key transcription factor for CXCL13 production in human CD4+ T cells under inflammatory conditions. [Nat Commun] Full Article Acquired Cancer Resistance to Combination Immunotherapy from Transcriptional Loss of Class I HLA Scientists treated two patients with metastatic Merkel cell carcinoma with autologous Merkel cell polyomavirus specific CD8+ T cells and immune-checkpoint inhibitors. In both cases, dramatic remissions were associated with dense infiltration of activated CD8+s into the regressing tumors. [Nat Commun] Full Article | Press Release Using a well-established macrophage differentiation protocol, knock-out of RIPK1 did not block the differentiation of induced pluripotent stem cell (iPSC)-derived macrophages, which displayed a similar phenotype to WT human iPSC-derived macrophages. [Cell Death Dis] Full Article FSD13 had a greater ability than wild-type IL-2 in stimulating CD4+ T, CD8+ T, and NK cell proliferation, enhancing the expression of CD69, CD183, CD44, and CD54 in these cells, and triggering cancer cell apoptosis. [Cell Death Dis] Full Article Monocytes from human T-cell lymphotropic virus type-1 (HTLV-1)-infected individuals exhibited important functional differences when compared to cells from uninfected donors. Using proteomic shot gun strategy, performed by nanoACQUITY-UPLC system, the authors analyzed monocytes isolated from peripheral blood of asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and uninfected individuals. [Sci Rep] Full Article VSIG-3 as a Ligand of VISTA Inhibits Human T Cell Function Investigators report that VSIG-3/IGSF11 is a ligand of the B7 family member VISTA/PD-1H and inhibits human T cell functions through a novel VSIG-3/VISTA pathway. [Immunology] Abstract Compared to healthy controls, CD14++ CD16–monocytes from septic patients with immune suppression displayed an increased binding of CCCTC-binding factor within the MHC-II locus combined with decreased transcription of class II major histocompatibility complex transactivator CIITA gene. [PLoS One] Full Article G-Quadruplex-Forming Oligodeoxyribonucleotides Activate Leukotriene Synthesis in Human Neutrophils Researchers showed that exogenous G-quadruplex-forming oligodeoxyribonucleotides significantly enhanced 5-lipoxygenase metabolite formation in human neutrophils exposed to Salmonella typhimurium bacteria. [J Biomol Struct Dyn] Abstract Subscribe to our sister publications: Immunology of Infectious Disease News & Immune Regulation News. | |
| |
REVIEWSModulation of Three Key Innate Immune Pathways for the Most Common Retinal Degenerative Diseases The authors highlight the role of three key immune pathways in the pathophysiology of major retinal degenerative diseases including diabetic retinopathy, age-related macular degeneration, and rare retinal dystrophies. [EMBO Mol Med] Full Article Visit our reviews page to see a complete list of reviews in the human immunology research field. | |
| |
INDUSTRY NEWSCell Medica announced the treatment of the first patient worldwide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma. [Cell Medica] Press Release AIVITA Biomedical Announces Treatment of First Patient in Phase II Ovarian Cancer Trial AIVITA Biomedical announced that it has dosed its first of 10 patients currently enrolled as part of its Phase II trial in patients with advanced ovarian cancer. The trial is designed to investigate AIVITA Biomedical’s patient-specific cancer treatment consisting of autologous dendritic cells loaded with autologous antigens from the patient’s tumor-initiating cells. [AIVITA Biomedical] Press Release Abzena, plc has signed an antibody humanization agreement with Tmunity Therapeutics, a clinical stage T cell therapy company and a leader in the development of new chimeric antigen receptor T cell therapies for the treatment of solid and hematological cancers. [Abzena, plc] Press Release Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors Regen BioPharma Inc. reported its researchers have identified a series of small molecule drugs that inhibit NR2F6 and also activate human immune cells ex-vivo. [Regen BioPharma Inc. (PR Newswire Association LLC.)] Press Release | |
| |
POLICY NEWSTrump Administration Launches Review of Scientific Research Involving Fetal Tissue The Trump administration has launched a comprehensive review of all research that involves fetal tissue, reopening an issue that has galvanized anti-abortion activists but worried scientists who fear their work could be under threat. [STAT News] Editorial Portrayals of Female STEM Characters in TV and Film Haven’t Improved in 10 Years The Lyda Hill Foundation, in partnership with Geena Davis’s Institute on Gender in Media at Mount Saint Mary’s University, released an extensive research report on the portrayals of female characters in science, technology, engineering and math in television and film. “Portray Her: Representations of Women STEM Characters in Media” shows that entertainment media has a long way to go to improve stereotypes about pursuing STEM careers. [EurekAlert] Editorial More and More Scientists Are Preregistering Their Studies. Should You? Preregistration, in its simplest form, is a one-page document answering basic questions such as: What question will be studied? What is the hypothesis? What data will be collected, and how will they be analyzed? In its most rigorous form, a “registered report,” researchers write an entire paper, minus the results and discussion, and submit it for peer review at a journal, which decides whether to accept it in principle. [ScienceInsider] Editorial
| |
EVENTSNEW Tumor Immunology and Immunotherapy Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Research Assistant II – Immunology (Baylor College of Medicine) Research Technologist – Immunology (STEMCELL Technologies Inc.) Faculty Position – Immunology (Benaroya Research Institute) Faculty Position – Systems Immunology (Benaroya Research Institute) Project Leader – Immuno-Oncology (CELLECTIS Inc.) Postdoctoral Fellowship – Immunology (University of Nantes) Postdoctoral Associates – Cancer Immunology and/or Bioinformatics (Emory University) Institute Group Leader – Lymphocyte Biology (MD Anderson Cancer Center) Postdoctoral Fellow – Cancer Therapeutics and Immunotherapy (Emory University) Faculty Position – Aging and the Immune System (Mayo Clinic) Postdoctoral Fellow – Immunotherapy (California Institute for Biomedical Research) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Human Immunology News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|